#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Eosinophilic granulomatosis with polyangiitis Infantile apnoea Skin cancer Granulomatosis with polyangiitis Gastrointestinal neuroendocrine tumour Mantle cell lymphoma Arginase deficiency HER2 gene amplification Small cell lung cancer limited stage Retinal dystrophy Cystic fibrosis gastrointestinal disease Nephroblastoma Encephalitis autoimmune Bronchiectasis Chondrosarcoma More trials…

    Learn about Rare Diseases

    Hypereosinophilic syndrome – Life with Disease Undifferentiated sarcoma – Life with Disease Brain stem glioma Haemophilia B with anti factor IX – Basic Information Choroid melanoma – Trials in Disease Progressive supranuclear palsy – Treatment Bronchopulmonary dysplasia – Life with Disease Cytokine release syndrome – Diagnostics Friedreich’s ataxia – Basic Information Hairy cell leukaemia recurrent – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    VISUGROMAB Elamipretide Trihydrochloride Trehalose Dihydrate (Ph.eur.) Nmd670 Brexpiprazole Fumarate HUMAN PLASMA Elezanumab Mocravimod Sucrose Citalopram Hydrochloride Dabigatran Tabelecleucel Elranatamab D-Biotin Colesevelam Testosterone Treprostinil Palmitil Ciltacabtagene Autoleucel Rivaroxaban AZD5335 More therapies…

    Learn about Your Condition

    Asymptomatic HIV infection Senile dementia Foot deformity Juvenile psoriatic arthritis Myeloproliferative neoplasm Rhabdoid tumour Latent tuberculosis Anaplastic thyroid cancer Paresis Ovarian cancer Barrett's oesophagus Critical illness Oesophageal achalasia Fibrous dysplasia of bone Cerebral palsy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Koranyi National Institute For Pulmonology

Koranyi National Institute For Pulmonology

Koranyi Frigyes Ut 1, Budapest, 1121, Hungary

Want to learn more about this study or check if you can participate? Contact us.

  • Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Siltuximab
    • Tarlatamab
    Belgium France Germany Greece Hungary Italy +5

  • Study for Patients with Lung or Urinary Tract Cancer Continuing Treatment with Durvalumab, Infliximab, and Mycophenolate Mofetil

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Durvalumab
    • Infliximab
    • Mycophenolate Mofetil
    Belgium Bulgaria Czechia France Germany Greece +5

  • Long‑term Safety of Adagrasib with Drug Combination in Adults with Solid Tumors

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Cetuximab
    • Adagrasib
    • Dexamethasone
    Belgium France Germany Greece Hungary Italy +5

  • Phase IIb Study of AZD8965 versus Placebo in Adults with Idiopathic Pulmonary Fibrosis

    Recruiting

    2 1
    Bulgaria Denmark France Germany Greece Hungary +4

  • Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Durvalumab
    Austria Belgium Bulgaria France Germany Greece +8

  • Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Pembrolizumab
    Austria Belgium Bulgaria Czechia Finland France +10

  • A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Atezolizumab
    • Carboplatin
    • Etoposide
    Austria Belgium Bulgaria Czechia Estonia Finland +14

  • Comparing Sotorasib and Pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Hydroxocobalamin
    • Sotorasib
    • Betamethasone Sodium Phosphate Ph. Eur
    Austria Belgium Bulgaria Czechia Denmark France +11

  • A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis

    Recruiting

    2 1
    Investigated Drugs:
    • HUMANISED IGG1 LALAPS-YTE MONOCLONAL ANTIBODY AGAINST LYSOPHOSPHATIDIC ACID RECEPTOR 1
    Bulgaria France Germany Greece Hungary Italy +5

  • A study comparing the effectiveness and safety of datopotamab deruxtecan and docetaxel in adults with advanced or metastatic non-squamous non-small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Datopotamab Deruxtecan
    • Docetaxel
    Austria Belgium France Germany Hungary Italy +2
1 2 3 … 9
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!